Sanofi Disease Education
Sanofi is committed to educating patients and healthcare professionals about
diseases and conditions. This section provides information about specific cancer
types and complications from cancer treatment for which there are unmet therapeutic needs and emerging information.
Learn more about:
1. Virág L, Szabó C. Pharmacol Rev. 2002;54(3):375-429. 2. Bryant HE, Helleday T.
Inhibition of poly(ADP-ribose) polymerase activates ATM which is required for subsequent
homologous recombination repair. Nucleic Acids Res. 2006;34(6):1685-1691. 3. Ashworth
A. J Clin Oncol. 2008;26(22):3785-3790. 4. Bryant HE, Helleday T. Poly(ADP-ribose)
polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans. 2004;32(Pt6):959-961.